Gemini Therapeutics Inc
NASDAQ:GMTX
Intrinsic Value
Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. [ Read More ]
The intrinsic value of one GMTX stock under the Base Case scenario is 4.5 USD. Compared to the current market price of 19.89 USD, Gemini Therapeutics Inc is Overvalued by 77%.
Valuation Backtest
Gemini Therapeutics Inc
Run backtest to discover the historical profit from buying and selling GMTX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Gemini Therapeutics Inc's business.
What risks and challenges
does Gemini Therapeutics Inc face in the near future?
Summarize the latest earnings report
of Gemini Therapeutics Inc.
Provide P/E
for Gemini Therapeutics Inc and its competitors.
Balance Sheet Decomposition
Gemini Therapeutics Inc
Current Assets | 198.5m |
Cash & Short-Term Investments | 194.6m |
Other Current Assets | 3.9m |
Non-Current Assets | 1.7m |
PP&E | 1.6m |
Other Non-Current Assets | 116k |
Current Liabilities | 22.6m |
Accounts Payable | 16.2m |
Accrued Liabilities | 6.4m |
Non-Current Liabilities | 1m |
Other Non-Current Liabilities | 1m |
Earnings Waterfall
Gemini Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-47.5m
USD
|
Operating Income
|
-47.5m
USD
|
Other Expenses
|
648k
USD
|
Net Income
|
-46.8m
USD
|
Free Cash Flow Analysis
Gemini Therapeutics Inc
What is Free Cash Flow?
GMTX Profitability Score
Profitability Due Diligence
Gemini Therapeutics Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Gemini Therapeutics Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
GMTX Solvency Score
Solvency Due Diligence
Gemini Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Gemini Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GMTX Price Targets Summary
Gemini Therapeutics Inc
Ownership
GMTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
GMTX Price
Gemini Therapeutics Inc
Average Annual Return | 9.9% |
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -93% |
Market Capitalization | 860.1m USD |
Shares Outstanding | 43 244 500 |
Percentage of Shares Shorted | 6.51% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2020-08-12. The firm is principally focused on developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). The firm's lead product candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. Its Pipeline of product candidate includes (adeno-associated virus) AAV-CFH, AAV-CFI, AAV-Ab, GEM104 and GEM307. Its AAV-CFH program is complementary to GEM103 program, as AAV-CFH to construct that express GEM103 continuously at a therapeutic level. Its pipeline is designed to develop treatments for genetically subpopulations of patients suffering from dry AMD and linked diseases. The firm do not own or operate manufacturing facilities for the production of clinical or commercial quantities of its product candidates.
Contact
IPO
Employees
Officers
The intrinsic value of one GMTX stock under the Base Case scenario is 4.5 USD.
Compared to the current market price of 19.89 USD, Gemini Therapeutics Inc is Overvalued by 77%.